TrialThe lancet. HIV2026

Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial.

Ming J Lee et al.PubMed ↗Publisher ↗

No numbers read from the abstract.